Microbial metabolites are rich sources for new potential therapeutic drugs [22]. Over 5000 antibiotics have been identified from the cultures of Gram-positive, Gramnega tive and filamentous fungi; but only about hundred antibiotics alone have been used commercially to treat the human, animal and plant diseases [2]. Industrial antibiotic production mainly focuses on screening programmes for identification of new potent antibiotic producing organisms either from natural sources or from established cultures [4]. Selective procedures which allow detection and isolation of only those microorganisms of interest from a large population were developed for screening [9]. The need for less toxic, more potent antibiotics from noninfective organisms, which overcome the resistance exhibited against the existing antibiotics are some of the challenges to the evolving therapeutics against microbial infections.